Could an allergy drug boost brain function in williams syndrome?

NCT ID NCT06087757

Ongoing Disease control Sponsor: Sheba Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether clemastine, a common allergy medication, can improve thinking, motor skills, and social abilities in people with Williams syndrome. The study includes 30 participants aged 6 to 30 and uses a double-blind, placebo-controlled design to measure safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: clemastine (an antihistamine allergy drug)
What this could lead to: If it works, this could point toward a treatment to improve thinking, movement, and social skills in people with Williams syndrome.
What could go wrong: This is a small, early-phase trial with only 30 people. The drug is being tested for a new purpose, so it may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WILLIAMS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Williams syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WILLIAMS SYNDROME

Contacts and locations

Locations

Child and Adolescent Psychiatry Unit, Sheba Medical Center

Ramat Gan, Israel
Tel Aviv University

Tel Aviv, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.